COVID-19 and Sex-/Gender-Specific Differences: Understanding the Discrimination

Ariunzaya Amgalan; Ann Kinga Malinowski; Maha Othman

doi:10.1055/s-0040-1715455

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2021; 47(04): 341-347
DOI: 10.1055/s-0040-1715455

Commentary

COVID-19 and Sex-/Gender-Specific Differences: Understanding the Discrimination

Ariunzaya Amgalan

¹Georgetown University School of Medicine, Washington, District of Columbia

,

Ann Kinga Malinowski

¹Georgetown University School of Medicine, Washington, District of Columbia

,

Maha Othman

²Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

³Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada

⁴School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada

› Author Affiliations

Abstract

Full Text

References

References
1 Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis 2020; 50 (01) 54-67
2 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
3 Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020; 507: 167-173
4 Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets 2020; 31 (06) 740-745
5 Knight M, Bunch K, Vousden N. et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK: national population based cohort study. BMJ 2020; 369: m2107
6 Kayem G, Lecarpentier E, Deruelle P. et al. A snapshot of the COVID-19 pandemic among pregnant women in France. J Gynecol Obstet Hum Reprod 2020; 49 (07) 101826
7 World Health Organization. SUBJECT IN FOCUS: WHO Global Case-Based Surveillance for Human Infection with Coronavirus Disease (COVID-19).; 2020. Accessed May 23, 2020 at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2
8 Peckham H, de Gruijter N, Raine C. et al. Sex-bias in COVID-19: a meta-analysis and review of sex differences in disease and immunity. Nat Commun 2020; (epub ahead of print)
9 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2020; 2 (08) 113-122
10 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
11 COVID-19 sex-disaggregated data tracker – Global Health 50/50. Accessed May 23, 2020 at: https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/#1587645651236-8a62beb3-4a03
12 Michelozzi P, de'Donato F, Scortichini M. et al. Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020. Euro Surveill 2020; 25 (19) 2000620
13 Di Lorenzo G, Di Trolio R. Coronavirus disease (COVID-19) in Italy: analysis of risk factors and proposed remedial measures. Front Med (Lausanne) 2020; 7: 140
14 Di Stadio A, Ricci G, Greco A, de Vincentiis M, Ralli M. Mortality rate and gender differences in COVID-19 patients dying in Italy: a comparison with other countries. Eur Rev Med Pharmacol Sci 2020; 24 (08) 4066-4067
15 Richardson S, Hirsch JS, Narasimhan M. et al; The Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323 (20) 2052-2059
16 Serge R, Vandromme J, Charlotte M. Are we equal in adversity? Does COVID-19 affect women and men differently?. Maturitas 2020; 138: 62-68
17 Grasselli G, Zangrillo A, Zanella A. et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323 (16) 1574-1581
18 Garg S, Kim L, Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (15) 458-464
19 Meng Y, Wu P, Lu W. et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLOS Pathog 2020; 16 (04) e1008520
20 Li X, Xu S, Yu M. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146 (01) 110-118
21 Lechien JR, Chiesa-Estomba CM, Place S. et al; COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020; 288 (03) 335-344
22 Luo H, Lie Y, Prinzen FW. Surveillance of coronavirus disease 2019 in general population using an online questionnaire: a report from 18161 respondents in China (preprint). JMIR Public Health Surveill 2020; 6 (02) e18576
23 Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 2010; 10 (08) 594-604
24 Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics 2019; 13 (01) 2
25 Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 2020; 34 (02) 339-343
26 vom Steeg LG, Klein SL. SeXX matters in infectious disease pathogenesis. PLoS Pathog 2016; 12 (02) e1005374
27 Amadori A, Zamarchi R, De Silvestro G. et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1995; 1 (12) 1279-1283
28 Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 2004; 65 (05) 476-485
29 Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009; 10 (05) 509-516
30 Buckberry S, Bianco-Miotto T, Bent SJ, Dekker GA, Roberts CT. Integrative transcriptome meta-analysis reveals widespread sex-biased gene expression at the human fetal-maternal interface. Mol Hum Reprod 2014; 20 (08) 810-819
31 Pinheiro I, Dejager L, Libert C. X-chromosome-located microRNAs in immunity: might they explain male/female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. BioEssays 2011; 33 (11) 791-802
32 Chamekh M, Deny M, Romano M. et al. Differential susceptibility to infectious respiratory diseases between males and females linked to sex-specific innate immune inflammatory response. Front Immunol 2017; 8: 1806
33 Sundrani DP, Roy SS, Jadhav AT, Joshi SR. Sex-specific differences and developmental programming for diseases in later life. Reprod Fertil Dev 2017; 29 (11) 2085-2099
34 Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol 2018; 9: 2279
35 Kadel S, Kovats S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front Immunol 2018; 9: 1653
36 Zeng F, Dai C, Cai P. et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol 2020; 25989
37 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
38 Sungnak W, Huang N, Bécavin C. et al; HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26 (05) 681-687
39 TMPRSS2 transmembrane serine protease 2 [Homo sapiens (human)] - Gene - NCBI. Accessed May 25, 2020 at: https://www.ncbi.nlm.nih.gov/gene/7113
40 Matsuyama S, Nao N, Shirato K. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020; 117 (13) 7001-7003
41 Camostat Mesylate in COVID-19 Outpatients - Full Text View - ClinicalTrials.gov. Accessed June 5, 2020 at: https://clinicaltrials.gov/ct2/show/NCT04353284
42 Brosnihan KB, Hodgin JB, Smithies O, Maeda N, Gallagher P. Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-α knock-out mice. Exp Physiol 2008; 93 (05) 658-664
43 Bukowska A, Spiller L, Wolke C. et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med (Maywood) 2017; 242 (14) 1412-1423
44 Mohamad N-V, Wong SK, Wan Hasan WN. et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male 2019; 22 (02) 129-140
45 Shivers KY, Amador N, Abrams L, Hunter D, Jenab S, Quiñones-Jenab V. Estrogen alters baseline and inflammatory-induced cytokine levels independent from hypothalamic-pituitary-adrenal axis activity. Cytokine 2015; 72 (02) 121-129
46 Bianchi VE. The anti-inflammatory effects of testosterone. J Endocr Soc 2018; 3 (01) 91-107
47 La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. Int J Mol Sci 2020; 21 (08) 2948
48 Rastrelli G, Di Stasi V, Inglese F. et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology 2020; 12821
49 Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol 2017; 198 (10) 4046-4053
50 Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020; 12 (02) 194
51 Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020; 8 (06) e46-e47
52 Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003; 38 (01) 13-22
53 Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy 2004; 3 (01) 97-104
54 Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med 2020; 382 (22) 2163-2164
55 Leclerc PM, Dubois-Colas N, Garenne M. Hormonal contraception and HIV prevalence in four African countries. Contraception 2008; 77 (05) 371-376
56 Rotermann M, Dunn S, Black A. Oral contraceptive use among women aged 15 to 49: results from the Canadian Health Measures Survey. Stat Canada 2015; 26 (10) 21-28
57 Sanal MG. RE: Oral contraceptive pills may be better and safe in the management of COVID-19 than chloroquine derivatives!. CMAJ 2020; 192 (17) E450-E453
58 Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020; 192 (17) E450-E453
59 Estrogen Patch for COVID-19 Symptoms - Full Text View - ClinicalTrials.gov. Accessed May 24, 2020 at: https://clinicaltrials.gov/ct2/show/NCT04359329
60 Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clin Sci (Lond) 2020; 134 (05) 543-545
61 Lei C, Fu W, Qian K. et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv 2020; Doi: org/10.1101/2020.02.01.929976
62 Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM. From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol 2014; 5: 227
63 Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?. Int J Mol Sci 2020; 21 (10) E3474
64 Liu J, Ji H, Zheng W. et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ 2010; 1 (01) 6
65 Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care 2020; 24 (01) 221
66 Chen J, Jiang Q, Xia X. et al. Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation. Preprints; 2020. Accessed May 24, 2020 at: www.preprints.org
67 Khan A, Benthin C, Zeno B. et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 2017; 21 (01) 234
68 Monteil V, Kwon H, Prado P. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181 (04) 905-913.e7
69 Valdés G, Neves LAA, Anton L. et al. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006; 27 (2-3): 200-207
70 Noymer A, Garenne M. The 1918 influenza epidemic's effects on sex differentials in mortality in the United States. Popul Dev Rev 2000; 26 (03) 565-581
71 Garenne M. Demographic evidence of sex differences in vulnerability to infectious diseases. J Infect Dis 2015; 211 (02) 331-332
72 Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2018; 315 (05) R895-R906
73 Elgendy IY, Pepine CJ. Why are women better protected from COVID-19: Clues for men? Sex and COVID-19. Int J Cardiol 2020; (epub ahead of print)
74 Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med 2020; 75: 107-108
75 Lippi G, Sanchis-Gomar F, Henry BM. Active smoking and COVID-19: a double-edged sword. Eur J Intern Med 2020; 77 (00) 123-124
76 Walter LA, McGregor AJ. Sex- and gender-specific observations and implications for COVID-19. West J Emerg Med 2020; 21 (03) 507-509
77 Suen LKP, So ZYY, Yeung SKW, Lo KYK, Lam SC. Epidemiological investigation on hand hygiene knowledge and behaviour: a cross-sectional study on gender disparity. BMC Public Health 2019; 19 (01) 401
78 Johnson HD, Sholcosky D, Gabello K, Ragni R, Ogonosky N. Sex differences in public restroom handwashing behavior associated with visual behavior prompts. Percept Mot Skills 2003; 97 (3, Pt 1): 805-810
79 Harris CR, Jenkins M. Gender differences in risk assessment: Why do women take fewer risks than men?. Judgment Decision Making 2006; 1 (01) 48-63
80 Karlberg J, Chong DSY, Lai WYY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?. Am J Epidemiol 2004; 159 (03) 229-231
81 Jin J-M, Bai P, He W. et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020; 8: 152